Monoclonal anti-D for immunoprophylaxis

Vox Sanguinis
M L Scott

Abstract

Routine antenatal prophylaxis with anti-D has become accepted as desirable, but concerns have been expressed about the adequacies of supply and safety of polyclonal anti-D. Human monoclonal anti-D has been produced using Epstein-Barr virus (EBV)-transformed peripheral B cells, sometimes coupled with fusions to myeloma cell lines. More recently, molecular biology techniques have been used to produce human monoclonal anti-D in a variety of different ways. Many monoclonal antibodies (mAbs) have been characterized for fine specificity and in vitro functional activity in International Workshops. Two mAbs have been shown to cause red cell clearance and immunosuppression in male volunteers. Considerations for the future development of monoclonal anti-D for prophylactic use are reviewed.

References

Aug 1, 1990·Journal of Immunogenetics·P Tippett, S Moore
Dec 1, 1990·British Journal of Haematology·K MayneP Tippett
Aug 1, 1990·Journal of Immunogenetics·B M Kumpel
Sep 1, 1988·Transfusion Medicine Reviews·J M Bowman
Sep 1, 1988·Transfusion Medicine Reviews·C LeveneN Manny
Apr 1, 1988·Revue française de transfusion et immuno-hématologie·P Tippett
May 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·D BronH S Kaplan
Sep 1, 1994·British Journal of Haematology·N C Hughes-JonesW H Ouwehand
Jan 1, 1996·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·M Scott
Jan 1, 1996·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·B M Kumpel
Dec 10, 1998·The New England Journal of Medicine·J M Bowman
Aug 24, 1999·European Journal of Immunology·K L ArmourL M Williamson
Nov 25, 2000·British Journal of Haematology·S MiescherF Wurm
Apr 5, 2001·Trends in Immunology·B M Kumpel, C J Elson

❮ Previous
Next ❯

Citations

Sep 11, 2002·Obstetrics and Gynecology
Nov 3, 2004·Clinics in Perinatology·Ursula F Harkness, Joseph A Spinnato

❮ Previous
Next ❯